Distinction Between Autoimmune and Non-Autoimmune Hyperthyroidism by Determination of TSH-Receptor Antibodies in Patients with the Initial Diagnosis of Toxic Multinodular Goiter

Distinguishing Graves’ disease (GD) from a toxic multinodular goiter (TMG) subgroup with a diffuse but uneven Tc-distribution depends on the diagnostic power of the TSH-receptor antibody (TRAb) determination. Bioassays using CHO cell lines expressing the hTSH-receptor or a new TBII assay, which uses the hTSH-receptor as an antigen (DYNOTEST TRAK human, Brahms, Germany), showed a higher sensitivity for the detection of TRAbs in patients with GD than assays using solubilized porcine epithelial cell membranes. The aim of this study was to investigate whether the new Dynotest TRAK human assay has an increased sensitivity to distinguish GD from non-autoimmune hyperthyroidism. Therefore, we examined 21 consecutive patients with the initial diagnosis of TMG for thyroid-stimulating antibodies (TSAbs, JP26 cell assay) and TBII with the new highly sensitive Dynotest TRAK human (Brahms, Germany). The initial diagnosis of TMG was based on suppressed TSH and a patchy Tc-uptake of more than 1 % and less than 7 % or TSH of more than 0.3 mIE/l with a patchy Tc-uptake of more than 1.5 % and less than 7 % and negative TBII values in a displacement assay using solubilized porcine epithelial cell membranes (TRAK, Brahms, Germany). 11 sera from these 21 patients showed TSAb activity. Furthermore, 10 of these 11 TSAb-positive sera were also positive in the Dynotest TRAK human assay, whereas one serum sample was borderline positive. TSAb activity and inhibition of ¹²⁵I-bTSH binding in the Dynotest TRAK human assay correlated well (r = 0.7). Therefore, 11 of the 21 investigated patients initially classified as TMG actually had GD, which was undetectable using the porcine TBII assay. In conclusion, TSAbs or TRAbs detected with the Dynotest TRAK human have the highest diagnostic power to differentiate GD from TMG. Because of the less cumbersome assay technique, the Dynotest TRAK human measurements should be obtained for all patients with non-typical TMG to differentiate GD from non-autoimmune hyperthyroidism in order to select the appropriate therapy for these patients.

Hyperthyroidism - TSH Receptor Antibodies - Toxic Multinodular Goiter - Grave's Disease

References

• 1 Laurberg P, Pedersen K M, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland.  J Intern Med. 1991;  229 415-420
• 2 Pedersen O M, Aardal N P, Larssen T B, Varhaug J E, Myking O, Vik-Mo H. The value of ultrasonography in predicting autoimmune thyroid disease (In Process Citation).  Thyroid. 2000;  10 251-259
• 3 Vitti P. Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease.  Eur J Endocrinol. 2000;  142 22-24
• 4 Carnell N E, Valente W A. Thyroid nodules in Graves' disease: classification, characterization, and response to treatment (published erratum appears in Thyroid 1998; 8: 1079).  Thyroid. 1998;  8 647-652
• 5 Kraiem Z, Glaser B, Yigla M, Pauker J, Sadeh O, Sheinfeld M. Toxic multinodular goiter: a variant of autoimmune hyperthyroidism.  J Clin Endocrinol Metab. 1987;  65 659-664
• 6 Rees S B, McLachlan S M, Furmaniak J. Autoantibodies to the thyrotropin receptor.  Endocr Rev. 1988;  9 106-121
• 7 Vitti P, Elisei R, Tonacchera M, et al. Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor.  J Clin Endocrinol Metab. 1993;  76 499-503
• 8 Costagliola S, Morgenthaler N G, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease.  J Clin Endocrinol Metab. 1999;  84 90-97
• 9 Wallaschofski H, Paschke R. Detection of thyroid stimulating (TSAb)-and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers.  Clin Endocrinol (Oxf.). 1999;  50 365-372
• 10 Huysmans A K, Hermus R M, Edelbroek M A, et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters.  Thyroid. 1977;  7 535-539
• 11 Huysmans D, Hermus A, Edelbroek M, Barentsz J, Corstens F, Kloppenborg P. Radioiodine for nontoxic multinodular goiter.  Thyroid. 1977;  7 235-239
• 12 Nygaard B, Faber J, Veje A, Hegedus L, Hansen J M. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.  Thyroid. 1999;  9 477-481
• 13 Nygaard B, Metcalfe R A, Phipps J, Weetman A P, Hegedus L. Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.  J Endocrinol Invest. 1999;  22 481-485
• 14 Vitti P, Rago T, Mancusi F, et al.. Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves' disease.  Acta Endocrinol (Copenh.). 1992;  126 128-131
• 15 Sostre S, Reyes M M. Sonographic diagnosis and grading of Hashimoto's thyroiditis.  J Endocrinol Invest. 1991;  14 115-121
• 16 Yoshida A, Adachi T, Noguchi T, et al. Echographic findings and histological feature of the thyroid: a reverse relationship between the level of echo-amplitude and lymphocytic infiltration.  Endocrinol Jpn. 1985;  32 681-690